A 2014 Cochrane review did not find a difference between bevacizumab and<unk>  in deaths or total severe side effects when used for macular degeneration. There, however, was not a lot of evidence, and thus this conclusion is not that certain.<unk>  does appear to result in a lower risk of stomach and intestinal problems. It is also associated with a low rate of eye related side effects. The most common side effects in clinical trials were conjunctival haemorrhage, eye pain, vitreous floaters, increased intraocular pressure, and intraocular inflammation. Although there is a theoretical risk for arterial thromboembolic events in people receiving VEGF-inhibitors by intravitreal injection, the observed incidence rate was low (< 4%) and similar to that seen with placebo. Serious adverse events related to the injection procedure occurred with an incidence rate of less than 1% and included endophthalmitis, retinal detachment, and traumatic cataracts. Other serious ocular adverse events observed among<unk> -treated patients (incidence rate < 1%) included intraocular inflammation and blindness.
Ranibizumab
Ruxolitinib
Abrocitinib
Gilteritinib
Erdafitinib
Sorafenib
Avelumab
Nintedanib